An antibody-drug conjugate called EBC-129 will be the first made-in-Singapore antibody-drug conjugate to be approved to enter clinical trials by the US Food and Drug Administration. This drug is able to selectively target cancer cells across a range of solid tumours -- killing it, while sparing normal, healthy cells. Dr Andre Choo, deputy executive director at A*STAR's Bioprocessing Technology Institute, and Dr Veronica Diermayr, asset development leader at the Experimental Drug Development Centre, shared more about the development process.
Subscribe to our channel here: [ Ссылка ]
Subscribe to our news service on Telegram: [ Ссылка ]
Follow us:
CNA: [ Ссылка ]
CNA Lifestyle: [ Ссылка ]
Facebook: [ Ссылка ]
Instagram: [ Ссылка ]
Twitter: [ Ссылка ]
TikTok: [ Ссылка ]
